Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers
Journal of Infectious Diseases, Volume 198, No. 10, Year 2008
Notification
URL copied to clipboard!
Description
Background. One strategy for improving anti-tuberculosis (TB) vaccination involves the use of recombinant bacille Calmette-Guérin (rBCG) overexpressing protective TB antigens. rBCG30, which overexpresses the Mycobacterium tuberculosis secreted antigen Ag85b, was the first rBCG shown to induce significantly greater protection against TB in animals than parental BCG. Methods. We report here the first double-blind phase 1 trial of rBCG30 in 35 adults randomized to receive either rBCG30 or parental Tice BCG intradermally. Clinical reactogenicity was assessed, and state-of-the-art immunological assays were used to study Ag85b-specific immune responses induced by both vaccines. Results. Similar clinical reactogenicity occurred with both vaccines. rBCG30 induced significantly increased Ag85b-specific T cell lymphoproliferation, interferon (IFN)-γ secretion, IFN-γ enzyme-linked immunospot responses, and direct ex vivo intracellular IFN-γ responses. Additional flow cytometry studies measuring carboxyfluorescein succinimidyl ester dilution and intracellular cytokine production demonstrated that rBCG30 significantly enhanced the population of Ag85b-specific CD4+ and CD8+ T cells capable of concurrent expansion and effector function. More importantly, rBCG30 significantly increased the number of Ag85b-specific T cells capable of inhibiting intracellular mycobacteria. Conclusions. These results provide proof of principal that rBCG can safely enhance human TB immunity and support further development of rBCG overexpressing Ag85b for TB vaccination. © 2008 by the Infectious Diseases Society of America. All rights reserved.
Authors & Co-Authors
Hoft, Daniel Fredric
United States
St. Louis University Medical Center
United States, St. Louis
St. Louis University School of Medicine
Blazevic, Azra
United States
St. Louis University Medical Center
Abate, Getahun
United States
St. Louis University Medical Center
Hanekom, Willem Albert
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Kaplan, Gilla
United States, Camden
University of Medicine and Dentistry
Soler, Jorge H.
United States, Camden
University of Medicine and Dentistry
Weichold, Frank F.
United States, Rockville
Aeras Global tb Vaccine Foundation
Geiter, Lawrence J.
United States, Rockville
Aeras Global tb Vaccine Foundation
Sadoff, Jerald C.
United States, Rockville
Aeras Global tb Vaccine Foundation
Horwitz, Marcus A.
United States, Los Angeles
University of California, Los Angeles
Statistics
Citations: 173
Authors: 10
Affiliations: 6
Identifiers
Doi:
10.1086/592450
ISSN:
00221899
Research Areas
Disability
Infectious Diseases
Study Design
Cross Sectional Study